UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 45

Sortiert nach

Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance

Risk management and healthcare policy, 2018-01, Vol.11, p.109-116

2018

Link zum Volltext

Verfügbarkeit prüfen

Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update

Drugs (New York, N.Y.), 2021, Vol.81 (1), p.125-156

2021

Link zum Volltext

Verfügbarkeit prüfen

Diagnosis and Treatment of ADHD in the United States: Update by Gender and Race

Journal of attention disorders, 2020-01, Vol.24 (1), p.10-19

2020

Link zum Volltext

Verfügbarkeit prüfen

All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population

Drug safety, 2018-02, Vol.41 (2), p.213-228

2018

Link zum Volltext

Verfügbarkeit prüfen

High-risk opioid prescribing trends in the outpatient setting prior to issuance of federal guidance

Preventive medicine reports, 2019-09, Vol.15, p.100892-100892, Article 100892

2019

Link zum Volltext

Verfügbarkeit prüfen

Characterization of hospitalized patients who received naloxone while receiving opioids with or without gabapentinoids

The mental health clinician, 2021-07, Vol.11 (4), p.225-230

2021

Link zum Volltext

Verfügbarkeit prüfen

Use of power-law analysis to predict abuse or diversion of prescribed medications: proof-of-concept mathematical exploration

BMC research notes, 2018-07, Vol.11 (1), p.523-523, Article 523

2018

Link zum Volltext

Verfügbarkeit prüfen

Gabapentinoid Pharmacology in the Context of Emerging Misuse Liability

Journal of clinical pharmacology, 2021-08, Vol.61 (S2), p.S89-S99

2021

Link zum Volltext

Verfügbarkeit prüfen

State-level response to gabapentin misuse in the United States: Implications and future direction

American journal of health-system pharmacy, 2022-04, Vol.79 (9), p.e143-e148

2022

Link zum Volltext

Verfügbarkeit prüfen

Receipt of Substance Use Counseling Among Ambulatory Patients Prescribed Opioids in the United States

Substance abuse : research and treatment, 2020, Vol.14, p.1178221819894588

2020

Link zum Volltext

Verfügbarkeit prüfen

Prevalence and characteristics of self-reported kratom use in a representative US general population sample

Journal of addictive diseases, 2020-10, Vol.38 (4), p.506-513

2020

Link zum Volltext

Verfügbarkeit prüfen

Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS)

Research in social and administrative pharmacy, 2019-08, Vol.15 (8), p.953-958

2019

Link zum Volltext

Verfügbarkeit prüfen

Combined Gabapentinoid and Opioid Use

Annals of internal medicine, 2019-06, Vol.170 (12), p.908

2019

Link zum Volltext

Verfügbarkeit prüfen

Subcutaneous Buprenorphine Extended-Release Use Among Pregnant and Postpartum Women

Obstetrics and gynecology (New York. 1953), 2021-02, Vol.137 (2), p.377

2021

Link zum Volltext

Verfügbarkeit prüfen

Drug–drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs

CNS spectrums, 2019-06, Vol.24 (3), p.287-312

2019

Link zum Volltext

Verfügbarkeit prüfen

Authors’ Reply to Bonnet et al. “Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update”

Drugs (New York, N.Y.), 2021-04, Vol.81 (5), p.615-617

2021

Link zum Volltext

Verfügbarkeit prüfen

Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states

Drug and alcohol dependence, 2022-08, Vol.237, p.109518-109518, Article 109518

2022

Link zum Volltext

Verfügbarkeit prüfen

Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample

International journal of clinical pharmacy, 2021-08, Vol.43 (4), p.1055-1064

2021

Link zum Volltext

Verfügbarkeit prüfen

Predictors of Gabapentin Overuse With or Without Concomitant Opioids in a Commercially Insured U.S. Population

Pharmacotherapy, 2018-04, Vol.38 (4), p.436-443

2018

Link zum Volltext

Verfügbarkeit prüfen

Management of Opioid Agonist Treatment for Opioid Use Disorder in the Setting of Solid Organ Transplant

Transplantation, 2022-05, Vol.106 (5), p.900

2022

Link zum Volltext

Verfügbarkeit prüfen

Opportunities to Offer Harm Reduction to People who Inject Drugs During Infectious Disease Encounters: Narrative Review

Open forum infectious diseases, 2020-11, Vol.7 (11), p.ofaa503

2020

Link zum Volltext

Verfügbarkeit prüfen

Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic

American journal of health-system pharmacy, 2021-03, Vol.78 (7), p.613-618

2021

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of Gabapentin Abuse: Comparison with Agents with Known Abuse Potential in a Commercially Insured US Population

Clinical drug investigation, 2017-08, Vol.37 (8), p.763-773

2017

Link zum Volltext

Verfügbarkeit prüfen

Pharmacist, prescriber, and drug policy expert opinions on gabapentinoid misuse

Research in social and administrative pharmacy, 2023-04, Vol.19 (4), p.599-609

2023

Link zum Volltext

Verfügbarkeit prüfen

Policies to mitigate nonmedical use of prescription medications: how should emerging evidence of gabapentin misuse be addressed?

Expert opinion on drug safety, 2018-05, Vol.17 (5), p.519-523

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 45

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(44)
Berichte
(1)

Sprache

Englisch
(45)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance

Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update

Diagnosis and Treatment of ADHD in the United States: Update by Gender and Race

All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population

High-risk opioid prescribing trends in the outpatient setting prior to issuance of federal guidance

Characterization of hospitalized patients who received naloxone while receiving opioids with or without gabapentinoids

Use of power-law analysis to predict abuse or diversion of prescribed medications: proof-of-concept mathematical exploration

Gabapentinoid Pharmacology in the Context of Emerging Misuse Liability

State-level response to gabapentin misuse in the United States: Implications and future direction

Receipt of Substance Use Counseling Among Ambulatory Patients Prescribed Opioids in the United States

Prevalence and characteristics of self-reported kratom use in a representative US general population sample

Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS)

Combined Gabapentinoid and Opioid Use

Subcutaneous Buprenorphine Extended-Release Use Among Pregnant and Postpartum Women

Drug–drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs

Authors’ Reply to Bonnet et al. “Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update”

Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states

Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample

Predictors of Gabapentin Overuse With or Without Concomitant Opioids in a Commercially Insured U.S. Population

Management of Opioid Agonist Treatment for Opioid Use Disorder in the Setting of Solid Organ Transplant

Opportunities to Offer Harm Reduction to People who Inject Drugs During Infectious Disease Encounters: Narrative Review

Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic

Prevalence of Gabapentin Abuse: Comparison with Agents with Known Abuse Potential in a Commercially Insured US Population

Pharmacist, prescriber, and drug policy expert opinions on gabapentinoid misuse

Policies to mitigate nonmedical use of prescription medications: how should emerging evidence of gabapentin misuse be addressed?

Suchergebnisse filtern